IL313568A - Distinct cell membrane protein variants of CD117 for use in cellular therapy - Google Patents
Distinct cell membrane protein variants of CD117 for use in cellular therapyInfo
- Publication number
- IL313568A IL313568A IL313568A IL31356824A IL313568A IL 313568 A IL313568 A IL 313568A IL 313568 A IL313568 A IL 313568A IL 31356824 A IL31356824 A IL 31356824A IL 313568 A IL313568 A IL 313568A
- Authority
- IL
- Israel
- Prior art keywords
- seq
- isoform
- cells
- cell
- chain variable
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4202—Receptors, cell surface antigens or cell surface determinants
- A61K40/4224—Molecules with a "CD" designation not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
- A61K40/22—Immunosuppressive or immunotolerising
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/50—Cellular immunotherapy characterised by the use of allogeneic cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- General Engineering & Computer Science (AREA)
- Developmental Biology & Embryology (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Virology (AREA)
- Pharmacology & Pharmacy (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21215028 | 2021-12-16 | ||
| EP22164796 | 2022-03-28 | ||
| EP22207926 | 2022-11-16 | ||
| PCT/EP2022/086452 WO2023111311A1 (en) | 2021-12-16 | 2022-12-16 | Discernible cell surface protein variants of cd117 for use in cell therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL313568A true IL313568A (en) | 2024-08-01 |
Family
ID=84981434
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL313568A IL313568A (en) | 2021-12-16 | 2022-12-16 | Distinct cell membrane protein variants of CD117 for use in cellular therapy |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250057951A1 (enExample) |
| EP (1) | EP4448573A1 (enExample) |
| JP (1) | JP2024546996A (enExample) |
| KR (1) | KR20240115920A (enExample) |
| AU (1) | AU2022409748A1 (enExample) |
| CA (1) | CA3240527A1 (enExample) |
| IL (1) | IL313568A (enExample) |
| MX (1) | MX2024007317A (enExample) |
| WO (1) | WO2023111311A1 (enExample) |
| ZA (1) | ZA202405110B (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023248126A1 (en) * | 2022-06-20 | 2023-12-28 | Crispr Therapeutics Ag | Chimeric antigen receptor specific to cd117 |
| IL317566A (en) * | 2022-07-07 | 2025-02-01 | Cimeio Therapeutics Ag | Antibodies targeting CD117 |
| WO2025231071A1 (en) * | 2024-05-01 | 2025-11-06 | Beam Therapeutics Inc. | Compositions and methods for cell conditioning |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0578774B1 (en) | 1991-04-05 | 1998-07-29 | The Board Of Regents Of The University Of Washington | Monoclonal antibodies to stem cell factor receptors |
| TWI395754B (zh) | 2006-04-24 | 2013-05-11 | Amgen Inc | 人類化之ｃ-ｋｉｔ抗體 |
| WO2015050959A1 (en) | 2013-10-01 | 2015-04-09 | Yale University | Anti-kit antibodies and methods of use thereof |
| WO2016020791A1 (en) | 2014-08-05 | 2016-02-11 | Novartis Ag | Ckit antibody drug conjugates |
| US11499168B2 (en) | 2016-04-25 | 2022-11-15 | Universitat Basel | Allele editing and applications thereof |
| LT3535392T (lt) | 2016-11-02 | 2024-04-25 | Universität Basel | Imunologiškai atpažįstami ląstelių paviršiaus variantai, skirti naudoti ląstelių terapijoje |
| RU2019130504A (ru) | 2017-02-28 | 2021-03-30 | Вор Байофарма, Инк. | Композиции и способы ингибирования линиеспецифических белков |
| TWI687227B (zh) * | 2017-10-03 | 2020-03-11 | 生倍科技股份有限公司 | 用於t細胞免疫療法之組合及其用途 |
| KR20200069364A (ko) | 2017-10-24 | 2020-06-16 | 마젠타 테라퓨틱스 인코포레이티드 | Cd117+ 세포의 고갈을 위한 조성물 및 방법 |
| WO2019084057A2 (en) * | 2017-10-24 | 2019-05-02 | Magenta Therapeutics, Inc. | COMPOSITIONS AND METHODS FOR DEPLOYING CD117 + CELLS |
| KR102835308B1 (ko) * | 2018-08-08 | 2025-07-21 | 드래곤플라이 쎄라퓨틱스, 인크. | Nkg2d, cd16 및 종양 관련 항원에 결합하는 단백질 |
| EA202190986A1 (ru) | 2018-11-26 | 2021-12-14 | Фоти Севен, Инк. | ГУМАНИЗИРОВАННЫЕ АНТИТЕЛА К c-Kit |
| WO2020219748A2 (en) * | 2019-04-24 | 2020-10-29 | Magenta Therapeutics, Inc. | Anti-cd117 antibodies and uses thereof |
| EP4022051A4 (en) | 2019-08-29 | 2024-01-10 | Beam Therapeutics Inc. | COMPOSITIONS AND METHODS FOR NON-TOXIC CONDITIONING |
-
2022
- 2022-12-16 EP EP22843648.1A patent/EP4448573A1/en active Pending
- 2022-12-16 MX MX2024007317A patent/MX2024007317A/es unknown
- 2022-12-16 CA CA3240527A patent/CA3240527A1/en active Pending
- 2022-12-16 AU AU2022409748A patent/AU2022409748A1/en active Pending
- 2022-12-16 WO PCT/EP2022/086452 patent/WO2023111311A1/en not_active Ceased
- 2022-12-16 JP JP2024536163A patent/JP2024546996A/ja active Pending
- 2022-12-16 US US18/719,780 patent/US20250057951A1/en active Pending
- 2022-12-16 KR KR1020247023745A patent/KR20240115920A/ko active Pending
- 2022-12-16 IL IL313568A patent/IL313568A/en unknown
-
2024
- 2024-06-28 ZA ZA2024/05110A patent/ZA202405110B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ZA202405110B (en) | 2025-12-17 |
| WO2023111311A1 (en) | 2023-06-22 |
| EP4448573A1 (en) | 2024-10-23 |
| CA3240527A1 (en) | 2023-06-22 |
| AU2022409748A1 (en) | 2024-05-23 |
| US20250057951A1 (en) | 2025-02-20 |
| JP2024546996A (ja) | 2024-12-26 |
| KR20240115920A (ko) | 2024-07-26 |
| MX2024007317A (es) | 2024-06-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10836831B2 (en) | Anti-PTK7 antibodies and methods of use | |
| CN103476429B (zh) | 新型调节剂及使用方法 | |
| US20250057951A1 (en) | Discernible cell surface protein variants of cd117 for use in cell therapy | |
| WO2023118608A1 (en) | Discernible cell surface protein variants of cd45 for use in cell therapy | |
| US20250326818A1 (en) | Discernible cell surface protein variants for use in cell therapy | |
| WO2024208836A1 (en) | Discernible cell surface protein variants of cd33 for use in cell therapy | |
| CN118401558A (zh) | 用于细胞疗法的cd117的可辨识细胞表面蛋白变体 | |
| WO2025031965A1 (en) | Discernible cell surface protein variants of cd52 for use in cell therapy | |
| CN117813110A (zh) | 用于在细胞治疗中使用的可辨别细胞表面蛋白变体 | |
| HK40044653A (en) | Novel modulators and methods of use | |
| HK1191031A (en) | Novel modulators and methods of use | |
| HK1191031B (en) | Novel modulators and methods of use |